DEDALUS & IBEX LAUNCH AI PATHOLOGY FOR CANCER DIAGNOSIS IN EUROPE
Dedalus and Ibex Launch an End-to-End AI-powered Digital Pathology Solution, Streamlining Cancer Diagnosis Across Europe
Milan, Italy, Nov 30th – Dedalus Group (“Dedalus”), the leading anatomic pathology information systems provider in Europe, and Ibex Medical Analytics (“Ibex”), the market leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the launch of a fully integrated End-to-End AI-powered Digital Pathology Solution for cancer diagnosis.
The new solution is now commercially available in major European markets and sets a new standard for anatomic pathology lab digitization by seamlessly integrating Ibex’s GalenTM platform into Dedalus’ comprehensive Digital Pathology (DP) Solution. It enables full digitization of anatomic pathology labs with a next-generation Anatomic Pathology Information System (AIS) & DP solution, harnessing the power of data and AI for assisted case prioritization, advanced image analysis, and reproducible diagnoses. The increasing demand for pathology services posed by the growing number of cancer patients and global shortage of trained pathologists, leads pathology laboratories to actively seek efficiency-enhancing solutions that enable labs to maintain high accuracy levels while reducing time to diagnosis and optimizing diagnostic workflows.